Avedro, Inc., a global ophthalmic medical device and pharmaceutical company, has announced that its research will be presented in seven scientific posters accepted at the Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO), in Fort Lauderdale, FL, May 6-12, 2012.
The poster presentations are authored by members of Avedroâ€™s science and research teams and offer new insights into corneal collagen cross-linking and in some cases challenge previously established science in the field.
The poster presentations cover a range of topics: 1. Interferometric system for topographic and biomechanical study of the cornea; 2. Implications of new absorption and fluorescence measurements of riboflavin for corneal cross-linking; 3. Thermal safety analysis for accelerated cross-linking with riboflavin; 4. Photochemical kinetics model of corneal cross-linking with riboflavin; 5. Feasibility study of riboflavin dosimetry via detection of riboflavin fluorescence; 6. Computer modeling study of corneal cross-linking with riboflavin; and 7. Biomechanical study of corneal cross-linking with riboflavin.
"Avedro has brought together a unique team of scientists, engineers and clinicians dedicated to the field of collagen cross-linking and corneal biomechanics,â€ť said Peter Hersh, MD, Medical Monitor and Director, Cornea and Laser Eye Institute. â€śTheir collaborative efforts are advancing our knowledge of these exciting new fields in ophthalmology and have enabled the development of new and innovative devices and drug formulations for improving the outcomes of refractive corrective procedures such as Lasik, and for treating progressive and debilitating eye diseases such as keratoconus."
â€śAvedroâ€™s research has made possible several technical breakthroughs that have been incorporated into our accelerated cross-linking devices and our family of proprietary riboflavin formulations,â€ť said David Muller, President and CEO of Avedro, â€śwhich together significantly increase the speed, precision, safety and efficiency of corneal collagen cross-linking. Recent advancements made possible through Avedroâ€™s research and development now have the exciting potential to correct myopia and astigmatism with cross-linking. Those applications are currently being investigated by Avedro in conjunction with the development of our KXLâ„˘ II System.â€ť
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal collagen cross-linking. The Companyâ€™s advanced cross-linking technology not only improves the treatment of keratoconus and post-Lasik ectasia, it has also enabled an entirely new cross-linking procedure, Lasik Xtraâ„˘, which is used during a LASIK procedure to restore the biomechanical integrity of the cornea following the creation of the LASIK flap. Avedro recentlyÂ submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeXâ„˘ (riboflavin ophthalmic solution)/KXLâ„˘System, making it the first company to seek approval for corneal cross-linking in the United States. Outside the United States, Avedro has obtained CE Mark for its VibeX riboflavin and KXL Systems for performing Lasik Xtra and accelerated corneal cross-linking.Business Wire
Last updated on: 02/05/2012